Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALZN

Alzamend Neuro Inc

Dec 12 • 04:00PM ET

1.19

Dollar change -0.01
Percentage change -0.83	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN LLY MRK ABBV AZN BMY BIIB REGN VRTX GILD

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.65	Insider Own	4.56%	Shs Outstand	5.23M	Perf Week	3.48%
Market Cap	5.33M	Forward P/E	-	EPS next Y	-3.50	Insider Trans	0.05%	Shs Float	4.27M	Perf Month	-22.22%
Income	-5.85M	PEG	-	EPS next Q	-0.38	Inst Own	0.94%	Short Float	3.11%	Perf Quarter	-38.34%
Sales	0.00M	P/S	-	EPS this Y	80.41%	Inst Trans	10.19%	Short Ratio	0.58	Perf Half Y	-79.01%
Book/sh	0.72	P/B	1.66	EPS next Y	-21.53%	ROA	-195.28%	Short Interest	0.13M	Perf Year	-87.98%
Cash/sh	0.91	P/C	1.30	EPS next 5Y	-	ROE	-1092.96%	52W Range	1.06 - 15.06	Perf YTD	-86.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-11.45%	ROI	-155.87%	52W High	-92.10%	Beta	-0.06
Dividend TTM	-	Quick Ratio	3.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	12.26%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	3.80	EPS Y/Y TTM	54.63%	Oper. Margin	-	RSI (14)	35.36	Volatility	8.29% 7.08%
Employees	7	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	35.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	91.29%	Payout	-	Rel Volume	0.28	Prev Close	1.20
Sales Surprise	-	EPS Surprise	47.48%	Sales Q/Q	-	Earnings	Sep 10	Avg Volume	228.25K	Price	1.19
SMA20	-6.67%	SMA50	-19.14%	SMA200	-73.00%	Trades		Volume	63,934	Change	-0.83%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-21	Initiated	Ascendiant Capital Markets	Buy	$8

Today 08:00AM	Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs (Business Wire)
Nov-19-24 08:00AM	Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
Oct-16-24 08:00AM	Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
07:30AM	EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
08:00AM	Loading…
Oct-15-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaq Listing Standards (Business Wire)
Oct-10-24 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Groups Virtual Healthcare Conference (Business Wire)
Aug-26-24 08:00AM	Alzamend Neuro Issues Letter to Stockholders (Business Wire) -7.47%
Aug-19-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder (Business Wire) +186.78%
Aug-12-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder (Business Wire)
Aug-06-24 08:00AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder (Business Wire) -9.84%
05:32AM	Alzamend Neuro partners with Mass General for Alzheimers treatment trial (Clinical Trials Arena)
Aug-05-24 09:09AM	Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimers Disease (Business Wire) -22.09%
07:30AM	EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
Jul-31-24 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
08:00AM	Loading…
Jul-12-24 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire)
May-22-24 08:00AM	Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Business Wire)
May-14-24 08:00AM	Alzamend Neuro Announces Initial Closing of Private Placement (Business Wire) +18.81%
May-09-24 09:30AM	EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga) +11.74%
08:00AM	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Business Wire)
May-07-24 08:00AM	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Business Wire) -20.02%
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Mar-26-24 05:52AM	ALZN Stock Earnings: Alzamend Neuro Misses EPS for Q3 2024 (InvestorPlace)
Dec-18-23 12:03PM	ALZN Stock Earnings: Alzamend Neuro Reported Results for Q2 2024 (InvestorPlace)
12:03PM	ALZN Stock Earnings: Alzamend Neuro Beats EPS for Q1 2024 (InvestorPlace)
Dec-11-23 09:30AM	EXCLUSIVE: Alzamend Neuro Plans To Kickstart Stress Disorder Study With Next-Gen Lithium Product Next Year (Benzinga) -6.54%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Business Wire)
Nov-20-23 08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a NextGeneration Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Business Wire) -17.75%
Nov-16-23 08:00AM	Alzamend Neuro Regains Compliance with Nasdaqs Minimum Bid Price Requirement (Business Wire)
Nov-13-23 08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire) -6.85%
08:00AM	Loading…
Oct-30-23 08:00AM	Alzamend Neuro Announces Reverse Stock Split (Business Wire) -24.62%
Oct-23-23 09:31AM	EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its NextGeneration Lithium Therapeutic Drug Candidate AL001 (Business Wire)
Oct-02-23 09:30AM	EXCLUSIVE: Alzamend Neuro To Start Next-Gen Therapy Study For Bipolar Disorder (Benzinga) -8.48%
08:00AM	Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Sep-22-23 08:00AM	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Business Wire)
Aug-30-23 09:30AM	EXCLUSIVE: Alzamend Seeks FDA Approval For Study For Upgraded Version Of Most Commonly Used Treatment For Bipolar Disorder (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Business Wire)
Jun-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Identifies Potential AL001 Dose Level For Upcoming Alzheimer's Study (Benzinga)
08:00AM	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Business Wire)
Jun-13-23 08:00AM	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever" Panel at the Maxim Groups Virtual Healthcare Conference (Business Wire)
May-24-23 08:00AM	3 Biotech Stocks That Could Turn $1,000 into $10,000 by 2024 (InvestorPlace) +10.30%
May-11-23 12:38PM	3 Penny Stocks That Could Turn $1,000 into $10,000 in a Year (InvestorPlace)
Apr-04-23 06:30AM	Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Apr-03-23 09:35AM	KILL Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) +15.29%
09:34AM	EXCLUSIVE: Alzamend Neuro Starts Phase 1/2A Trial For Its Alzheimer's Immunotherapy Vaccine (Benzinga)
08:50AM	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Mar-22-23 09:30AM	EXCLUSIVE: Alzamend Neuro Completes Clinical Portion Of Mid-Stage Alzheimer's Trial (Benzinga)
08:00AM	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-17-23 07:09AM	We Think Alzamend Neuro (NASDAQ:ALZN) Needs To Drive Business Growth Carefully (Simply Wall St.) -12.36%
Mar-16-23 08:00AM	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Business Wire)
Jan-26-23 08:00AM	Alzamend Neuro to Present at Sequire Biotechnology Conference (Business Wire) +9.48%
Jan-04-23 08:00AM	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Business Wire)
Dec-28-22 08:00AM	Alzamend Neuro Partners With the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for ALZN002 Phase I/IIA Immunotherapy Vaccine Clinical Trial to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire) -11.31%
07:31AM	EXCLUSIVE: Alzamend Neuro Partners With Stem Cell Institute For Immunotherapy Vaccine Trial For Dementia (Benzinga)
Dec-13-22 03:52PM	10 Biotech Stocks With The Biggest Upside (Insider Monkey)
Nov-22-22 08:05AM	In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc. (ACCESSWIRE) +10.62%
Nov-15-22 08:00AM	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Business Wire)
Oct-31-22 08:00AM	Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Oct-11-22 10:03AM	Alzamend Neuro, Inc.'s (NASDAQ:ALZN) top owners are individual investors with 46% stake, while 21% is held by private companies (Simply Wall St.) -11.19%
Oct-05-22 12:45PM	Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial (Benzinga) +7.25%
08:00AM	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimers Subjects (Business Wire)
Sep-29-22 12:29PM	Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study (Benzinga)
08:00AM	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimers Type (Business Wire)
Sep-22-22 08:00AM	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Business Wire) -7.63%
Aug-25-22 07:13AM	We Think Alzamend Neuro (NASDAQ:ALZN) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-24-22 08:41AM	6 Penny Stocks With 1,000% Upside Potential (InvestorPlace)
Jul-18-22 10:42AM	Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate (Benzinga)
08:00AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire)
Jun-20-22 09:22AM	10 Best Biotech Penny Stocks To Buy Now (Insider Monkey)
Jun-03-22 08:00AM	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational (Business Wire)
May-17-22 08:00AM	Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Business Wire) +7.25%
May-06-22 09:02AM	10 Biotech Penny Stocks Redditors Love (Insider Monkey) -6.74%
May-05-22 08:00AM	Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
May-04-22 06:25AM	What Kind Of Investors Own Most Of Alzamend Neuro, Inc. (NASDAQ:ALZN)? (Simply Wall St.)
Apr-28-22 06:30AM	BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
06:30AM	Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Apr-11-22 08:00AM	Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimers (Business Wire) -6.25%
Apr-06-22 10:15AM	10 Biotech Penny Stocks with Growth Catalysts (Insider Monkey)
Apr-04-22 08:00AM	Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board (Business Wire)
Mar-28-22 08:00AM	Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Mar-18-22 06:31AM	We're Hopeful That Alzamend Neuro (NASDAQ:ALZN) Will Use Its Cash Wisely (Simply Wall St.) +9.71%
Jan-13-22 04:00AM	ALZN: Coordinated Offensive on Alzheimers Disease (Zacks Small Cap Research)
Dec-17-21 09:54AM	Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate (Benzinga)
09:00AM	Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimers (Business Wire)
Dec-14-21 06:35PM	Why Alzamend Neuro Stock Soared Today (Motley Fool) +28.33% -15.91%
11:18AM	MIND Stock: The U.S. Navy Deal That Has Mind Technology Shares Surging Today (InvestorPlace)
09:29AM	ALZN Stock Alert: What Is Going on With Alzamend Neuro Today? (InvestorPlace)
Nov-30-21 08:30AM	Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimers (Business Wire)
Nov-11-21 07:17AM	28 Stocks Moving in Thursday's Pre-Market Session (Benzinga) +11.63%
Oct-01-21 09:24AM	Company News for Oct 1, 2021 (Zacks) -6.49%
04:44AM	51 Biggest Movers From Yesterday (Benzinga)
Sep-30-21 01:45PM	See Why Alzamend Neuro Stock Is Rallying On Thursday (Benzinga) +35.09%
12:09PM	36 Stocks Moving In Thursday's Mid-Day Session (Benzinga)
11:54AM	Why Alzamend Neuro Shares Are Surging Higher Today (Benzinga)
10:11AM	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients Immunological System to Combat Alzheimers Disease (Business Wire)
Sep-16-21 06:09AM	ALZN: An Elemental Approach to Alzheimers Disease (Zacks Small Cap Research)
Sep-15-21 06:29AM	Could The Alzamend Neuro, Inc. (NASDAQ:ALZN) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Sep-13-21 06:30AM	Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimers Disease (Business Wire) -5.76%
Aug-17-21 10:59AM	Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate (Benzinga) -5.71%

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AULT MILTON C III	Director	Aug 06 '24	Buy	2.75	75	206	77,268	Aug 14 06:01 PM
AULT MILTON C III	Director	Jul 31 '24	Buy	3.74	25	93	77,193	Aug 01 05:20 PM
AULT MILTON C III	Director	Apr 19 '24	Buy	0.69	1,000	688	771,699	Apr 23 08:00 PM
AULT MILTON C III	Director	Apr 01 '24	Buy	0.91	334	304	770,699	Apr 03 05:00 PM
AULT MILTON C III	Director	Jan 05 '24	Buy	1.06	2,000	2,127	770,365	Apr 01 04:30 PM
AULT MILTON C III	Director	Jan 05 '24	Buy	1.02	5,000	5,092	768,365	Jan 09 04:30 PM
AULT MILTON C III	10% Owner	Dec 26 '23	Buy	0.90	500	450	26,032	Dec 27 04:30 PM
AULT MILTON C III	10% Owner	Dec 22 '23	Buy	0.92	200	185	166,866	Dec 27 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALZN

Alzamend Neuro Inc

Upgrade your FINVIZ experience